[go: up one dir, main page]

NO951200L - Ny fremgangsmåte for forestring av baccatin-III og 10-desacetyl-baccatin-III - Google Patents

Ny fremgangsmåte for forestring av baccatin-III og 10-desacetyl-baccatin-III

Info

Publication number
NO951200L
NO951200L NO951200A NO951200A NO951200L NO 951200 L NO951200 L NO 951200L NO 951200 A NO951200 A NO 951200A NO 951200 A NO951200 A NO 951200A NO 951200 L NO951200 L NO 951200L
Authority
NO
Norway
Prior art keywords
iii
radical
pct
formula
image
Prior art date
Application number
NO951200A
Other languages
English (en)
Other versions
NO313141B1 (no
NO951200D0 (no
Inventor
Jean-Noel Denis
Andrew Greene
Jean-Manuel Mas
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO951200D0 publication Critical patent/NO951200D0/no
Publication of NO951200L publication Critical patent/NO951200L/no
Publication of NO313141B1 publication Critical patent/NO313141B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19951200A 1992-10-05 1995-03-29 Estere av baccatin-III og 10-desacetyl-baccatin-III, deres fremstilling samt mellomprodukter NO313141B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9211739A FR2696464B1 (fr) 1992-10-05 1992-10-05 Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
PCT/FR1993/000965 WO1994007876A1 (fr) 1992-10-05 1993-10-04 Nouveau procede d'esterification de la baccatine iii et de la desacetyl-10 baccatine iii

Publications (3)

Publication Number Publication Date
NO951200D0 NO951200D0 (no) 1995-03-29
NO951200L true NO951200L (no) 1995-03-29
NO313141B1 NO313141B1 (no) 2002-08-19

Family

ID=9434116

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19951200A NO313141B1 (no) 1992-10-05 1995-03-29 Estere av baccatin-III og 10-desacetyl-baccatin-III, deres fremstilling samt mellomprodukter

Country Status (24)

Country Link
US (2) US5717103A (no)
EP (1) EP0663905B1 (no)
JP (1) JP3064419B2 (no)
KR (1) KR100290663B1 (no)
AT (1) ATE147734T1 (no)
AU (1) AU689446B2 (no)
CA (1) CA2146372C (no)
CZ (1) CZ284818B6 (no)
DE (1) DE69307526T2 (no)
DK (1) DK0663905T3 (no)
ES (1) ES2096328T3 (no)
FI (1) FI115909B (no)
FR (1) FR2696464B1 (no)
GR (1) GR3022286T3 (no)
HU (1) HU225973B1 (no)
MX (1) MX9305764A (no)
NO (1) NO313141B1 (no)
NZ (1) NZ256443A (no)
PL (1) PL178090B1 (no)
RU (1) RU2123493C1 (no)
SK (1) SK281035B6 (no)
TW (1) TW372234B (no)
WO (1) WO1994007876A1 (no)
ZA (1) ZA937316B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU7138894A (en) * 1993-06-11 1995-01-03 Pharmacia & Upjohn Company Delta 6,7--taxols antineoplastic use and pharmaceutical compositions containing them
EP1652539B8 (en) 1993-07-19 2011-06-15 Angiotech Pharmaceuticals, Inc. Method of manufacturing a stent comprising an anti-angiogenic composition
EP0728130A1 (en) * 1993-11-12 1996-08-28 PHARMACIA & UPJOHN COMPANY Pyrimidine-thioalkyl and alkylether compounds
IL127597A (en) * 1994-01-28 2003-07-31 Upjohn Co Iso-taxol analogs
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
CZ293508B6 (cs) * 1996-05-08 2004-05-12 Pharmaciaá@Áupjohnácompany Fenylisoserinestery silylového baccatinu III
US6150537A (en) * 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
JP4502338B2 (ja) * 1999-09-17 2010-07-14 株式会社横浜国際バイオ研究所 タキソイド化合物の製造法
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
EP1318794A2 (en) 2000-09-22 2003-06-18 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
EP1418945A2 (en) * 2001-03-13 2004-05-19 Angiotech Pharmaceuticals, Inc. Micellar drug delivery vehicles and uses thereof
EP1392254B1 (en) * 2001-04-20 2007-06-06 The University of British Columbia Micellar drug delivery systems for hydrophobic drugs
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ITMI20021921A1 (it) * 2002-09-10 2004-03-11 Indena Spa Funzionalizzazione della posizione 14 dei nuclei tassanici e sintesi di nuovi derivati antitumorali.
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
EP2043704B2 (en) 2006-06-30 2017-04-19 Cook Medical Technologies LLC Methods of manufacturing and modifying taxane coatings for implantable medical devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
CN102046647A (zh) * 2008-06-06 2011-05-04 哈博生物科学公司 制备17-炔基-7-羟基甾族化合物和相关化合物的方法
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
KR102332790B1 (ko) 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
DK3107899T3 (da) 2014-02-19 2020-11-16 Aviv Therapeutics Inc Mitokondriel aldehyddehydrogenase 2 (aldh2)-bindende polycykliske amider og anvendelse deraf til cancerbehandling
JP6083815B2 (ja) * 2014-03-07 2017-02-22 立川ブラインド工業株式会社 タッセル
EP3352796B1 (en) 2015-09-25 2025-03-05 U.S. Tianyou Capital Corp Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
JP7109427B2 (ja) 2016-06-01 2022-07-29 セルヴィエ アイピー ユーケー リミテッド ポリアルキレンオキシド-アスパラギナーゼの製剤ならびにその製造法および使用法
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
AU2018211081B2 (en) 2017-01-18 2025-01-02 Bioatla, Inc. Chimeric antigen receptors against Axl or Ror2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111065623B9 (zh) 2017-05-24 2024-10-25 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
BR112020015520A2 (pt) 2018-01-31 2021-02-02 Galera Labs, Llc terapia de combinação para câncer com complexo de anel macrocíclico pentaaza e agente anticâncer à base de platina
AU2019249215A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
CA3129883A1 (en) 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
KR20220004653A (ko) 2019-04-02 2022-01-11 켄조케티 바이오테크놀러지 인코포레이티드 유출 펌프-암 항원 다중특이적 항체 및 그것과 관련된 조성물, 시약, 키트 및 방법
WO2021116943A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
JP2023512196A (ja) 2020-01-29 2023-03-24 ケンジョッケティ バイオテクノロジー,インク. 抗mdr1抗体およびその使用
CN116323662A (zh) 2020-06-04 2023-06-23 肯乔克蒂生物技术股份有限公司 抗abcg2抗体及其用途
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
US20220033784A1 (en) 2020-07-14 2022-02-03 Pfizer Inc. Recombinant vaccinia virus
CN116490522A (zh) 2020-09-02 2023-07-25 肯乔克蒂生物技术股份有限公司 抗abcc1抗体及其应用
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
MX2023005979A (es) 2020-11-20 2023-08-11 Scherer Technologies Llc R P Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco.
EP4448007A1 (en) 2021-12-13 2024-10-23 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34277A (en) * 1862-01-28 Improvement in lamps
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.

Also Published As

Publication number Publication date
NZ256443A (en) 1996-07-26
GR3022286T3 (en) 1997-04-30
PL178090B1 (pl) 2000-02-29
ES2096328T3 (es) 1997-03-01
NO313141B1 (no) 2002-08-19
HU225973B1 (en) 2008-02-28
US5977375A (en) 1999-11-02
JP3064419B2 (ja) 2000-07-12
RU95110766A (ru) 1996-12-27
ATE147734T1 (de) 1997-02-15
DE69307526D1 (de) 1997-02-27
DK0663905T3 (da) 1997-02-03
JPH08501787A (ja) 1996-02-27
CA2146372C (fr) 2003-09-09
CA2146372A1 (fr) 1994-04-14
DE69307526T2 (de) 1997-05-22
EP0663905B1 (fr) 1997-01-15
KR950703545A (ko) 1995-09-20
HU9500970D0 (en) 1995-06-28
ZA937316B (en) 1994-04-22
FR2696464A1 (fr) 1994-04-08
CZ83995A3 (en) 1995-09-13
EP0663905A1 (fr) 1995-07-26
TW372234B (en) 1999-10-21
CZ284818B6 (cs) 1999-03-17
AU5114893A (en) 1994-04-26
NO951200D0 (no) 1995-03-29
FI951593L (fi) 1995-04-04
RU2123493C1 (ru) 1998-12-20
FI951593A0 (fi) 1995-04-04
AU689446B2 (en) 1998-04-02
FR2696464B1 (fr) 1994-11-10
FI115909B (fi) 2005-08-15
HUT72616A (en) 1996-05-28
PL308239A1 (en) 1995-07-24
WO1994007876A1 (fr) 1994-04-14
SK43895A3 (en) 1995-08-09
MX9305764A (es) 1995-01-31
KR100290663B1 (ko) 2001-09-17
US5717103A (en) 1998-02-10
SK281035B6 (sk) 2000-11-07

Similar Documents

Publication Publication Date Title
NO951200D0 (no) Ny fremgangsmåte for forestring av baccatin-III og 10-desacetyl-baccatin-III
FI951595A0 (fi) Menetelmä taksaanijohdannaisten valmistamiseksi
DE69307527D1 (de) Verfahren zur herstellung von taxan-derivaten
NO951203D0 (no) Fremgangsmåte for fremstilling av taxanderivater
FI943644A0 (fi) Uudet happoanhydridit, niiden valmistus ja käyttö

Legal Events

Date Code Title Description
MK1K Patent expired